Meeting in Havana between Jorge Luis Perdomo Di-Lella, Cuban vice prime minister, and Candace Johnson, president and executive director of the North American scientific center.

Photo: @JorgeLuisPerd20

The license for collaboration in biotechnology that is being developed between Cuba and the Roswell Park Cancer Institute of the United States (RPCI) was renewed until November 30, 2027 by the authorities of the northern country.

This was revealed in a meeting in Havana between Jorge Luis Perdomo Di-Lella, Cuban vice prime minister, and Candace Johnson, president and executive director of the North American scientific center.

The US directive highlighted the relationships of trust between the institutions of both parties, which in 2018 formed the joint venture Innovative Immunotherapy Alliance, SA

He pointed out that Cuban scientists are very innovative and develop the resolution of problems from different approaches, so many good things can come out of this bilateral collaboration between the RPCI and the Center for Molecular Immunology (CIM), of the Antillean nation.

I had the pleasure of receiving Ms. Candance Johnson, President of the Roswell Park Cancer Institute of the #USA and her delegation.

We exchanged on scientific collaboration with Cuban biotechnology institutions.#Cuba pic.twitter.com/3YevHZlxXh

– Jorge Luis Perdomo (@JorgeLuisPerd20) January 24, 2023

For his part, Perdomo Di-Lella thanked the close alliance between both scientific centers,

Among the topics examined was the interest of the RPCI in taking advantage of the capacities to strengthen alliances with the Cuban Ministry of Public Health in the oncological area, with joint clinical investigations, the report refers.

Also present during the meeting were Carlos Fernández de Cossío, Vice Minister of Foreign Affairs;

Dr. Eduardo Martínez Díaz, president of the BioCubaFarma business group, and other representatives of the RPCI.

In September 2018, Innovative Immunotherapy Alliance, SA was established as a user of the Mariel Special Development Zone, with the purpose of researching, developing and marketing innovative Cuban medicines for the benefit of cancer patients in the United States, including the CIMAvax-EGF therapeutic lung cancer vaccine.

(With information from Prensa Latina)

See also:

Study between the CIM and the Roswell Park Institute of the USA reveals a new strategy to fight cancer